Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 3/20 | 0.62 |
| ▸ | TACR1 | P25103 | 3/20 | 0.62 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nolpitantium SCHEMBL2142512 | 1.00 | TACR2 (0.62) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29388081 | 1.00 | TACR2 (0.62) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL7561842 | 0.99 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29405138 | 0.99 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29721569 | 0.99 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL1650319 | 0.99 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29457709 | 0.95 | TACR2 (0.56) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL157084 | 0.95 | TACR2 (0.56) | TACR2TACR1CCR5 | |
| Hydrochloric Acid SCHEMBL29907320 | 0.90 | TACR2 (0.50) | TACR2TACR1CCR5 | |
| SCHEMBL8969597 | 0.88 | TACR2 (0.53) | TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| EP-0912174-B1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH NON-PEPTIDAL NEURIKININ-1 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2004-04-28 | — | — | EP | claimed |
| US-20030215456-A1 | Method of treating cancer | YAO SUI-LONG (US) | 2003-11-20 | — | — | US | claimed |
| US-6525073-B2 | For achieving circadian rhythm phase-shifting effect in mammal | MERCK & CO. INC. | 2003-02-25 | — | — | US | claimed |
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MERCK & CO., INC. | 2002-03-21 | — | — | US | claimed |
| EP-0981340-B1 | PHARMACEUTICAL FORMULATIONS IN DRY FORM FOR THE ORAL ADMINISTRATION OF A CYCLIC QUATERNARY AMMONIUM COMPOUND | SANOFI SYNTHELABO (FR) | 2001-12-12 | — | — | EP | claimed |
| US-6329401-B1 | PREVENTION OR TREATMENT OF SLEEP DISORDER; BY ADMINISTERING A CNS PENETRATING NEUROKININ-1 RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-12-11 | — | — | US | claimed |
| US-6303626-B1 | FOR ORAL ADMINISTRATION | SANOFI-SYNTHELABO (FR) | 2001-10-16 | — | — | US | claimed |
| US-6274604-B1 | ADMINISTERING A NEUROKININ-1 RECEPTOR ANTAGONIST TO ACHIEVE A CIRCADIAN RYTHM PHASE-SHIFTING TO IMPROVE THE QUALITY OF SLEEP | MERCK & CO., INC. | 2001-08-14 | — | — | US | claimed |
| US-6034105-A | NEUROKININ RECEPTOR ANTAGONIST; SLEEP DISORDERS | MERCK & CO., INC. (US) | 2000-03-07 | — | — | US | claimed |
| EP-0591040-B1 | Quaternary basic amides as tachykinines antagonists | SANOFI SA (FR) | 1999-02-03 | — | — | EP | claimed |
| EP-0591040-A1 | Quaternary basic amides as tachykinines antagonists | SANOFI (FR) | 1994-04-06 | — | — | EP | claimed |
| US-20050208095-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-22 | — | — | US | disclosed |
| US-20050183731-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050182463-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | disclosed |
| EP-0591040-B1 | Quaternary basic amides as tachykinines antagonists | SANOFI SA (FR) | 1999-02-03 | — | — | EP | disclosed |
| WO-1998002158-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | MERCK & CO., INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| EP-0612716-B1 | Process for the preparation of an optically pure aminoalcohol | SANOFI SA (FR) | 1996-05-08 | — | — | EP | disclosed |
| EP-0591040-A1 | Quaternary basic amides as tachykinines antagonists | SANOFI (FR) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MTNR1A, PROKR1, NTSR2 | TACR2 33/4885TACR1 45/4885CCR5 3044/4885 |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | TACR2 41/4885TACR1 34/4885CCR5 289/4885 |
| US-20030215456-A1 | Method of treating cancer | TACR1, TACR2, KLK3 | TACR2 2/4885TACR1 1/4885CCR5 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.